gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 08 Dec 2016.

Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein

Id1, Inhibitor of Differentiation, IDH, IDP, IDH1
The protein encoded by this gene is a helix-loop-helix (HLH) protein that can form heterodimers with members of the basic HLH family of transcription factors. The encoded protein has no DNA binding activity and therefore can inhibit the DNA binding and transcriptional activation ability of basic HLH proteins with which it interacts. This protein may play a role in cell growth, senescence, and differentiation. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CAN, HAD, p53, AGE, Methylguanine-DNA Methyltransferase
Papers using Id1 antibodies
Does RNA editing play a role in the development of urinary bladder cancer?
Supplier
Gallo Angela et al., In International Journal of Cancer. Journal International du Cancer, 2008
... (ID1) human heart from Clonthech, BD Biosciences; (ID2) human bladder from ...
Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways.
Supplier
Swarbrick Alexander, In PLoS ONE, 2002
... Id1 transgenic mice on the FVB/N ...
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations.
Supplier
Vooijs Marc, In PLoS ONE, 2000
... , we generated a mouse carrying a transgene encoding murine Id1 cDNA under the control of the modified tetracycline response element, TREtight (Clontech).
Electrical stimulation of neonatal cardiomyocytes results in the sequential activation of nuclear genes governing mitochondrial proliferation and differentiation
Supplier
Gundersen Kristian et al., In The Journal of Cell Biology, 1996
... ) and Id-1 (MId) transgenes were inserted into the genome of mice by conventional transgenic techniques described previously ( ...
Papers on Id1
Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
New
Tien et al., Taipei, Taiwan. In Expert Rev Hematol, Feb 2016
Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogenetics.
Cerebrospinal fluid metabolomics identifies a key role of isocitrate dehydrogenase in bipolar disorder: evidence in support of mitochondrial dysfunction hypothesis.
New
Hashimoto et al., Chiba, Japan. In Mol Psychiatry, Feb 2016
Furthermore, gene expression of two subtypes (IDH3A and IDH3B) of isocitrate dehydrogenase (IDH) in the dorsolateral prefrontal cortex from BD patients was significantly lower than that of controls, although the expression of other genes including, aconitase (ACO1, ACO2), IDH1, IDH2 and IDH3G, were not altered.
Idh1 mutations contribute to the development of T-cell malignancies in genetically engineered mice.
New
Mak et al., Toronto, Canada. In Proc Natl Acad Sci U S A, Feb 2016
UNASSIGNED: Gain-of-function mutations in isocitrate dehydrogenase 1 (IDH1) are key drivers of hematopoietic malignancies.
IDH mutation is associated with higher risk of malignant transformation in low-grade glioma.
New
Mariani et al., Basel, Switzerland. In J Neurooncol, Feb 2016
UNASSIGNED: Acquisition of IDH1 or IDH2 mutation (IDHmut) is among the earliest genetic events that take place in the development of most low-grade glioma (LGG).
Structural and functional features of the NAD(P) dependent Gfo/Idh/MocA protein family oxidoreductases.
Review
New
Rouvinen et al., Joensuu, Finland. In Protein Sci, Feb 2016
UNASSIGNED: The Gfo/Idh/MocA protein family contains a number of different proteins, which almost exclusively consist of NAD(P)-dependent oxidoreductases that have a diverse set of substrates, typically pyranoses.
Insulator dysfunction and oncogene activation in IDH mutant gliomas.
New
Impact
Bernstein et al., Boston, United States. In Nature, Feb 2016
Gain-of-function IDH mutations are initiating events that define major clinical and prognostic classes of gliomas.
Integrated genomic characterization of IDH1-mutant glioma malignant progression.
New
Impact
Günel et al., New Haven, United States. In Nat Genet, Jan 2016
To understand the molecular mechanisms underlying the malignant progression of low-grade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor samples from 41 patients, comparing higher-grade, progressed samples to their lower-grade counterparts.
Myelodysplastic syndromes: Contemporary review and how we treat.
Review
New
Tefferi et al., Rochester, United States. In Am J Hematol, Jan 2016
With the advent of next generation sequencing, recurrent somatic mutations in genes involved in epigenetic regulation (TET2, ASXL1, EZH2, DNMT3A, IDH1/2), RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2), DNA damage response (TP53), transcriptional regulation (RUNX1, BCOR, ETV6) and signal transduction (CBL, NRAS, JAK2) have been identified in MDS.
The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas.
Review
New
Louis et al., Bangkok, Thailand. In J Neuropathol Exp Neurol, Jan 2016
This review summarizes the current experience using immunohistochemistry of glioma samples to identify mutations in IDH1, TP53, ATRX, histone H3 genes, BRAF, EGFR, MGMT, CIC, and FUBP1 as well as guidelines for prudent use of DNA sequencing as a supplemental method.
Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
New
Impact
Cahill et al., Boston, United States. In Cancer Cell, Jan 2016
Heterozygous mutation of IDH1 in cancers modifies IDH1 enzymatic activity, reprogramming metabolite flux and markedly elevating 2-hydroxyglutarate (2-HG).
Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma.
New
Naccarato et al., Pisa, Italy. In Oncol Lett, Dec 2015
The 19 samples were molecularly characterized for mutations in the isocitrate dehydrogenase 1 (IDH1) gene, amplification of the epidermal growth factor receptor (EGFR) gene, presence of the EGFR variant III, and methylation of the promoter region of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene.
Myeloproliferative neoplasms: Current molecular biology and genetics.
Review
New
Saeidi, Kermān, Iran. In Crit Rev Oncol Hematol, Dec 2015
Some other genes' location such as TET oncogene family member 2 (TET2), additional sex combs-like 1 (ASXL1), casitas B-lineage lymphoma proto-oncogene (CBL), isocitrate dehydrogenase 1/2 (IDH1/IDH2), IKAROS family zinc finger 1 (IKZF1), DNA methyltransferase 3A (DNMT3A), suppressor of cytokine signaling (SOCS), enhancer of zeste homolog 2 (EZH2), tumor protein p53 (TP53), runt-related transcription factor 1 (RUNX1) and high mobility group AT-hook 2 (HMGA2) have also identified to be involved in MPNs phenotypes.
The Molecular Taxonomy of Primary Prostate Cancer.
New
Impact
Cancer Genome Atlas Research Network et al., In Cell, Dec 2015
Our results revealed a molecular taxonomy in which 74% of these tumors fell into one of seven subtypes defined by specific gene fusions (ERG, ETV1/4, and FLI1) or mutations (SPOP, FOXA1, and IDH1).
Spatiotemporal Evolution of the Primary Glioblastoma Genome.
New
Impact
Nam et al., Seoul, South Korea. In Cancer Cell, Oct 2015
In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen.
Identification of novel pathogenic gene mutations in pediatric acute myeloid leukemia by whole-exome resequencing.
Review
Shiba, In Rinsho Ketsueki, 2014
A new class of gene mutations, identified in the pathogenesis of adult acute myeloid leukemia (AML), includes DNMT3A, IDH1/2, TET2 and EZH2.
D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
GeneRIF
Mak et al., Toronto, Canada. In Genes Dev, 2012
Brain-specific Idh1-KI mice show brain hemorrhage accompanied by high D2HG levels but decreased ROS
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics.
Impact
GeneRIF
Mak et al., Toronto, Canada. In Nature, 2012
this study is the first to describe the generation and characterization of conditional IDH1(R132H)-KI mice, and also the first report to demonstrate the induction of a leukaemic DNA methylation signature in a mouse model; this report thus sheds light on t
IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
GeneRIF
Santosh et al., Bengaluru, India. In Am J Clin Pathol, 2012
Our study validates IDH1 mutant protein expression across various grades of astrocytoma, and demonstrates a high incidence of IDH1 mutations in DA, AA, and secondary GBM
IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
GeneRIF
Ando et al., Tokyo, Japan. In Biochem Biophys Res Commun, 2012
These results suggest that IDH1 and IDH2 have roles in production of D-2-hydroxyglutarate in cells.
ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21.
Impact
GeneRIF
Dick et al., Toronto, Canada. In Cancer Cell, 2012
Data show that regulation of p21 by ID1 and ID3 is a central mechanism preventing the accumulation of excess DNA damage and subsequent functional exhaustion of cancer-initiating cells (C-ICs).
share on facebooktweetadd +1mail to friends